Telisotuzumab clinical trial phase effects and safety

Telisotuzumab (Telisotuzumab vedotin, referred to as Teliso-V) is an innovative antibody conjugate drug (ADC) that targets METreceptor tyrosine kinase is mainly used to treat patients with advanced non-small cell lung cancer (NSCLC) with overexpression or gene amplification of MET. In clinical trials, Telisotuzumab demonstrated impressive efficacy and safety performance, becoming an emerging treatment option targeting the MET pathway.

First, Telisotuzumab has shown significant anti-tumor activity in multiple early-stage clinical trials (such as Phase I and II studies). Especially among patients who have received standard treatment in the past and whose tumors express high levels of MET, the objective response rate (ORR) has reached over 30%, and some patients have achieved sustained disease control. Research data shows that the drug can effectively target and kill MET positive tumor cells, slow down tumor progression, and significantly extend progression-free survival (PFS).

In terms of safety,Telisotuzumab’s side effects are generally controllable. Common adverse reactions include fatigue, nausea, alopecia and mild bone marrow suppression (such as neutropenia), most of which are grade 1-2 and are well tolerated. A small number of patients may develop peripheral neuropathy, which is a unique toxicity of ADC drugs. However, through dose adjustment and symptom management, most patients can continue treatment without serious effects.

Overall, Telisotuzumab is a promising drug for METADCtargeted drugs have shown good anti-tumor effects and safety in clinical trials, providing new treatment hope for patients with MET positive non-small cell lung cancer. With the follow-upIIIWith the advancement of phase 1 clinical trials, we look forward to its wider clinical application in the future and bringing good news to more patients.

Reference materials:https://www.drugs.com/